CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 74 enrolled
Drug / intervention
Silodosindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06282731
NCT06282731Early Ph 1Completed
CompareCT.gov

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia After Medical Treatment

En Chu Kong Hospital·interventional·Posted Feb 28, 2024·Updated Feb 28, 2024

In Brief

A Early Phase 1 clinical trial evaluating Silodosin for Benign Prostatic Hyperplasia. Completed, enrolled 74 participants across 1 site.

Detailed Summary

The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia after medical treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesTaiwan
Collaborators--

Timeline

Early Ph 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 28, 2024
Enrollment StartMay 31, 2013
Primary CompletionSep 1, 2016
Study CompletionApr 27, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 2.3 years ago

Interventions

Silodosindrug

Indications:Benign prostate hyperplasia